IP Library Granted Patent US 10,632,129
Granted Patent B2
US 10,632,129 · App. 15/528,452 · Granted Apr 28, 2020

Preservative-free treprostinil formulations and methods and devices for use with same

Inventors: Jonathan Rigby (San Ramon, CA); Peter Noymer (Los Gatos, CA); Robert Zwolinski (Napa, CA)
Assignee: SteadyMed Ltd.
A61K31/5575A61K9/0019A61M5/14248C07C39/17C07C59/72C07C405/0075
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,129
App. No.
15/528,452
Granted
Apr 28, 2020
Kind
B2
Abstract

This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/mL and 25 mg/mL in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof.

Claims (13)

1. A unit dosage form of treprostinil in a sterile fluid composition formulated for subcutaneous or intravenous injection, wherein:

said composition does not comprise an antimicrobial preservative,

said treprostinil is present at a dosage of between 0.1 mg/mL and 25 mg/mL,

said treprostinil is treprostinil sodium,

said composition comprises sodium chloride,

the composition comprises a sodium ion from sodium chloride in a concentration from 3000 to 4500 ppm, and

said composition does not comprise metacresol.

2. The unit dosage form of claim 1 , wherein said composition provides for a maximal volume of injection which does not exceed 10 mL for single use.

3. The unit dosage form of claim 1 , wherein the pH of the composition is from 6.5 to 6.7.

4. The unit dosage form of claim 1 , wherein the composition further comprises dextrose or glycerol.

5. The unit dosage form of claim 1 , wherein the composition does not comprise cresols, phenols, parabens, or benzyl alcohol.

6. A method of reducing pain at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof, wherein said subject is administered the unit dosage form of claim 1 .

7. A method of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof, wherein said subject is administered the unit dosage form of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2022
From: STEADYMED LTD.
To: UNITED THERAPEUTICS CORPORATION
Reel/Frame 060520/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2017
From: RIGBY, JONATHAN; NOYMER, PETER; ZWOLINSKI, ROBERT
To: STEADYMED LTD.
Reel/Frame 044411/0343 →